Investor Presentation
Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell therapy platform, is pleased to provide an update to investors in the form of the attached presentation.
The presentation will be used in Arovella’s non-deal investor meetings being conducted this week in Singapore and Hong Kong.
